Interventional - Drug
Restless legs syndrome (RLS) affects 30% of dialysis patients, and is associated with a decreased quality of life.
RLS is more common in patients with kidney disease compared to the general population, the pathophysiology is poorly understood, and current evidence for RLS in end stage renal disease (ESRD) patients is lacking.
The DISCO-RLS study aims to determine whether a fixed, low-dose combination therapy may be beneficial to target the multiple pathways implicated in the pathophysiology of RLS in individuals with kidney disease, while avoiding exposure to higher doses of medications that are associated with adverse events.
DISCO-RLS is a four-treatment crossover randomized controlled trial with a single blind double placebo run-in period.
David Collister, Nephrology Research Fellow, is also a key team member on the DISCO-RLS study.DISCO-RLS Slides - Download PDF
Interventional - Drug
Single blind double placebo RCT
2019 - 2022
Michael Walsh is a Principal Investigator in the Renal research program at PHRI, and an Assistant Professor, Department of Medicine (nephrology), McMaster University. His research activities are in the areas of the treatment of patients who require dialysis, severe glomerular disease, and perioperative acute kidney injury. He has published more than 70 papers and two book chapters.
He holds a Kidney Research Scientist Core Education and National Training (KRESCENT) Program New Investigator award through CIHR and the Kidney Foundation of Canada. He’s received multiple Top Abstract awards from the Canadian Society of Nephrology, the Chalmers Prize from the Society for Clinical Trials, and the Detweiller Traveling Scholar Award from the College of Physicians and Surgeons of Canada.
Tara McCready, PhD, oversees a variety of collaborative programs at PHRI, and serves as Project Manager for PHRI research studies and registries.
She was recruited to PHRI as a Program Director for the Canadian Network and Centre for Trials Internationally (CANNeCTIN), a national network funded by the CIHR/CFI Clinical Research Initiative program to improve the prevention and treatment of cardiac and vascular diseases and diabetes.
Previously the Executive Director of the Canadian Maternal, Infant, Child and Youth Research Network, Tara holds a PhD in Biochemistry and a MBA in Technology Commercialization from the University of Alberta.
David Collister is a nephrologist at the University of Alberta Hospital and Assistant Professor in the Department of Medicine, Division of Nephrology, at the University of Alberta. He completed a PhD in Health Research Methodology at McMaster University and research fellowship at the Population Health Research Institute (PHRI) focused on run-in periods and patient oriented research in kidney disease including the DISCO-RLS trial.
His research program focuses on symptom management in patients with kidney disease and, in particular, randomized controlled trials of therapies to alleviate symptoms in chronic kidney disease and dialysis. He currently holds a Kidney Research Scientist Core Education and National Training (KRESCENT) New Investigator Award. His research program is funded by the Canadian Institutes of Health Research and the Kidney Foundation of Canada. He is the principal investigator of RESET-DIALYSIS, a prospective cohort study of patients with advanced chronic kidney disease initiating dialysis which will examine the responsiveness of uremic symptoms to dialysis and uremic symptom pathophysiology with metabolomics, proteomics and genomics. He is the principal investigator of DISCO-POT, a randomized controlled trial of nabilone versus placebo for the treatment of uremic pruritus in adults with kidney failure treated with dialysis. He is also interested in the intersection between transgender, non-binary and gender diverse populations and kidney disease.
Senior Research Coordinator
Courtney has more than eight years of experience working in both industry and academic research. She primarily manages large international drug trials that focus primarily on prevention of cardiovascular disease (TIPS-3, COMPASS and ORIGIN trials) and chronic kidney disease (ACHIEVE, RECORD and DISCO-RLS trials).
She hold an Honours Bachelor of Applied Sciences with a Major in Kinesiology and a Diploma in Fitness and Health Promotion from the University of Guelph-Humber.
Back To Top